ad

3 Pharmaceuticals Maker, Fertilisers and Chemicals Company and Engineering and Construction Major Stocks With a Strong Future Roadmap: Torrent Pharmaceuticals, Chambal Fertilisers and Chemicals and Larsen & Toubro

Torrent Pharmaceuticals, Chambal Fertilisers and Chemicals and Larsen & Toubro: ROE of 14.7% to 25.5% and FY22 to FY26 revenue CAGR of 6.7% to 16.4%. Prices as of 16 Nov 2026.


17 Nov 2026 • 2:43 pm

3 Pharmaceuticals Maker, Fertilisers and Chemicals Company and Engineering and Construction Major Stocks With a Strong Future Roadmap: Torrent Pharmaceuticals, Chambal Fertilisers and Chemicals and Larsen & Toubro

Quick Answer

The three pharma, fertiliser and engineering major stocks to watch are Torrent Pharmaceuticals, Chambal Fertilisers and Chemicals and Larsen & Toubro. Their return on equity ranges from 14.7% to 25.5%, and their revenue compound annual growth from FY22 to FY26 ranges from 6.7% to 16.4%. Torrent Pharmaceuticals has the highest return on equity at 25.5%, while Larsen & Toubro has the fastest revenue growth at 16.4% a year. Prices are based on the 16 November 2026 close, and this article is educational, not investment advice.

Pharma, fertiliser and engineering major stocks give investors a way to track businesses that sit close to everyday demand in India. Torrent Pharmaceuticals, Chambal Fertilisers and Chemicals and Larsen & Toubro cover a pharmaceuticals maker, a fertilisers and chemicals company and an engineering and construction major.

This list covers three pharma, fertiliser and engineering major stocks with complete current figures: Torrent Pharmaceuticals, Chambal Fertilisers and Chemicals and Larsen & Toubro. Every figure comes from the latest reported financials and the 16 November 2026 market close. Companies without complete current figures were left out.

Click Here – Get Free Investment Predictions

What Are Pharma, Fertiliser and Engineering Major Stocks?

Pharma, fertiliser and engineering major stocks are listed companies that make and sell branded medicines for chronic care, make urea and other fertilisers for farmers, and build large infrastructure, energy and defence projects. Their earnings depend on medicine demand, farm activity and project orders.

Pharma, Fertiliser and Engineering Major Stocks at a Glance

Company CMP (Rs) Market Cap (Rs Cr) P/E Industry P/E ROE (%) D/E
Torrent Pharmaceuticals 4,691.2 173,079 80.3 36.0 25.5 1.79
Chambal Fertilisers and Chemicals 371.5 15,339 8.0 21.2 18.8 0.10
Larsen & Toubro 4,140 501,514 25.6 21.9 14.7 1.15

On valuation, Chambal Fertilisers and Chemicals trades at a P/E below the industry P/E, while Torrent Pharmaceuticals and Larsen & Toubro trade above it, which reflects the growth the market already expects. Readers comparing pharma, fertiliser and engineering major stocks should look at return on equity and debt together, since a high return earned with low debt is easier to sustain.

Why Do Pharma, Fertiliser and Engineering Major Stocks Have a Strong Roadmap in India?

Pharma, fertiliser and engineering major stocks have a strong roadmap in India because steady demand for chronic care medicines, steady farm activity and heavy infrastructure spending keep widening the market for these companies.

  • Pharmaceuticals. Chronic patients need regular medicines.
  • Fertilisers. Farmers need crop nutrients.
  • Engineering and construction. Large projects need proven builders.

Why Torrent Pharmaceuticals Features Among These Pharma, Fertiliser and Engineering Major Stocks

Among the pharma, fertiliser and engineering major stocks on this list, Torrent Pharmaceuticals is an Ahmedabad-based pharma company that leads in cardiovascular, central nervous system and gastro-intestinal therapies in India, with a growing presence in Brazil, Germany and the United States.

The company has a return on equity of 25.5%, a debt to equity ratio of 1.79 and a market capitalisation of Rs 173,079 crore. The stock trades at a P/E of 80.3, above the industry P/E of 36.0.

Revenue rose from Rs 8,705 crore in FY22 to Rs 13,886 crore in FY26, a compound annual growth rate of 12.4%. Net profit grew from Rs 777 crore in FY22 to Rs 2,138 crore in FY26, which works out to a compound annual growth rate of 28.8%. In the June 2026 quarter, revenue grew 56.3% year on year to Rs 4,909 crore, while net profit rose 3.3% to Rs 566 crore.

Roadmap: The company has strengthened its domestic position through acquisition of established brands and focuses on chronic therapies, where repeat prescriptions support sales. Its overseas markets contribute a steady share of revenue and add geographic balance.

What to watch: Watch the integration of newly acquired brands and the progress of margin improvement in the enlarged business.

Why Chambal Fertilisers and Chemicals Features Among These Pharma, Fertiliser and Engineering Major Stocks

Among the branded drug maker, urea maker and project builder shares on this list, Chambal Fertilisers and Chemicals makes urea at its plants in Rajasthan and trades in other fertilisers, crop protection chemicals and agri inputs.

Revenue rose from Rs 16,137 crore in FY22 to Rs 20,921 crore in FY26, a compound annual growth rate of 6.7%. Net profit grew from Rs 1,566 crore in FY22 to Rs 1,953 crore in FY26, which works out to a compound annual growth rate of 5.7%.

The company has a return on equity of 18.8%, a debt to equity ratio of 0.10 and a market capitalisation of Rs 15,339 crore. The stock trades at a P/E of 8.0, below the industry P/E of 21.2.

Roadmap: The company has a strong urea franchise with large volumes and a wide dealer network. It is widening into crop protection and specialty agri inputs, which adds higher-margin revenue to the base fertiliser business.

What to watch: Track fertiliser subsidy policy updates and the monsoon, which both influence volumes and working capital.

Why Larsen & Toubro Features Among These Pharma, Fertiliser and Engineering Major Stocks

Among the three companies on this list, Larsen and Toubro is a Mumbai-based engineering and construction conglomerate that builds infrastructure, energy and defence projects and also runs technology services, financial services and electronics businesses.

In the June 2026 quarter, revenue grew 8.1% year on year to Rs 70,318 crore, while net profit rose 15.2% to Rs 4,983 crore. Revenue rose from Rs 158,788 crore in FY22 to Rs 291,635 crore in FY26, a compound annual growth rate of 16.4%.

Net profit grew from Rs 10,291 crore in FY22 to Rs 19,159 crore in FY26, which works out to a compound annual growth rate of 16.8%. The company has a return on equity of 14.7%, a debt to equity ratio of 1.15 and a market capitalisation of Rs 501,514 crore. The stock trades at a P/E of 25.6, above the industry P/E of 21.9.

Roadmap: The company has a very large order book across infrastructure, energy and hydrocarbon projects, supported by government capital spending. Its growing technology and green energy businesses widen its sources of growth.

What to watch: Monitor order inflows, project execution and government infrastructure spending.

Torrent Pharmaceuticals vs Chambal Fertilisers and Chemicals vs Larsen & Toubro on Key Financials

The table below sets the three pharma, fertiliser and engineering major stocks side by side on revenue, profit and margin, using reported figures.

Company FY22 Revenue (Rs Cr) FY26 Revenue (Rs Cr) Revenue CAGR (FY22-FY26) FY26 Net Profit (Rs Cr) FY26 Net Margin
Torrent Pharmaceuticals 8,705 13,886 12.4% 2,138 15.4%
Chambal Fertilisers and Chemicals 16,137 20,921 6.7% 1,953 9.3%
Larsen & Toubro 158,788 291,635 16.4% 19,159 6.6%

Torrent Pharmaceuticals posts the highest return on equity in this group at 25.5%. Larsen & Toubro combines the largest FY26 revenue at Rs 291,635 crore with the fastest revenue growth, a 16.4% compound annual rate. A useful habit with pharma, fertiliser and engineering major stocks is to check each new quarterly result against the capacity plans the company described earlier.

Key Risks to Check Before Investing in Pharma, Fertiliser and Engineering Major Stocks

Every theme carries risks that deserve a check before any decision. For these pharma, fertiliser and engineering major stocks, the main points are: Long-term branded drug maker, urea maker and project builder shares holders usually track revenue growth, margins and cash flow side by side rather than relying on a single ratio.

  • Regulatory approvals. Plant inspections and approvals can affect supplies.
  • Season and monsoon. Crop protection sales follow rain and pest cycles.
  • Order timing. Project awards can shift between periods.

Treat this list as a starting point for research and not as a recommendation. Read the latest results presentation, check the management commentary on order books or capacity plans, and compare each company with its peers before you decide anything.

Use the Univest Stock Screener to filter pharma, fertiliser and engineering major stocks by market capitalisation, P/E, ROE and growth, and build your own shortlist.

Final Thoughts on Pharma, Fertiliser and Engineering Major Stocks

Pharma, fertiliser and engineering major stocks work best when investors track growth, valuation and return on equity side by side. Torrent Pharmaceuticals, Chambal Fertilisers and Chemicals and Larsen & Toubro each have a clear plan to grow. Based on the 16 November 2026 close, Torrent Pharmaceuticals trades at Rs 4,691.2, Chambal Fertilisers and Chemicals at Rs 371.5 and Larsen & Toubro at Rs 4,140. Valuation matters as much as growth, so compare each company's P/E with its industry P/E before adding any of these pharma, fertiliser and engineering major stocks to a watchlist.

Download the Univest iOS App or Univest Android App to track pharma, fertiliser and engineering major stocks, set price alerts and get research-backed stock ideas.

Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).

What are pharma, fertiliser and engineering major stocks?

Ans. Pharma, fertiliser and engineering major stocks are listed companies that make and sell branded medicines for chronic care, make urea and other fertilisers for farmers, and build large infrastructure, energy and defence projects. Their earnings depend on medicine demand, farm activity and project orders. This list looks at three of them, Torrent Pharmaceuticals, Chambal Fertilisers and Chemicals and Larsen & Toubro, using reported FY22 to FY26 financials and the 16 November 2026 closing prices.

Which pharma, fertiliser and engineering major stocks are covered in this list?

Ans. This list covers Torrent Pharmaceuticals, Chambal Fertilisers and Chemicals and Larsen & Toubro. Based on the 16 November 2026 close, Torrent Pharmaceuticals traded at Rs 4,691.2, Chambal Fertilisers and Chemicals at Rs 371.5 and Larsen & Toubro at Rs 4,140. Their return on equity ranges from 14.7% to 25.5%, and their revenue compound annual growth from FY22 to FY26 ranges from 6.7% to 16.4%.

Why do pharma, fertiliser and engineering major stocks have a strong future roadmap in India?

Ans. Pharma, fertiliser and engineering major stocks have a strong roadmap in India because steady demand for chronic care medicines, steady farm activity and heavy infrastructure spending keep widening the market for these companies. The main drivers are as follows. Pharmaceuticals. Chronic patients need regular medicines. Fertilisers. Farmers need crop nutrients. Engineering and construction. Large projects need proven builders. Together these factors give the companies on this list a visible path for growth over the coming years.

How has Torrent Pharmaceuticals performed financially?

Ans. Revenue rose from Rs 8,705 crore in FY22 to Rs 13,886 crore in FY26, a compound annual growth rate of 12.4%. Net profit grew from Rs 777 crore in FY22 to Rs 2,138 crore in FY26, which works out to a compound annual growth rate of 28.8%. In the June 2026 quarter, revenue grew 56.3% year on year to Rs 4,909 crore, while net profit rose 3.3% to Rs 566 crore. The company has a return on equity of 25.5%, a debt to equity ratio of 1.79 and a market capitalisation of Rs 173,079 crore. The stock trades at a P/E of 80.3, above the industry P/E of 36.0. Looking ahead, the company has strengthened its domestic position through acquisition of established brands and focuses on chronic therapies, where repeat prescriptions support sales. Its overseas markets contribute a steady share of revenue and add geographic balance.

How has Chambal Fertilisers and Chemicals performed financially?

Ans. Revenue rose from Rs 16,137 crore in FY22 to Rs 20,921 crore in FY26, a compound annual growth rate of 6.7%. Net profit grew from Rs 1,566 crore in FY22 to Rs 1,953 crore in FY26, which works out to a compound annual growth rate of 5.7%. The company has a return on equity of 18.8%, a debt to equity ratio of 0.10 and a market capitalisation of Rs 15,339 crore. The stock trades at a P/E of 8.0, below the industry P/E of 21.2. Looking ahead, the company has a strong urea franchise with large volumes and a wide dealer network. It is widening into crop protection and specialty agri inputs, which adds higher-margin revenue to the base fertiliser business.

How has Larsen & Toubro performed financially?

Ans. Revenue rose from Rs 158,788 crore in FY22 to Rs 291,635 crore in FY26, a compound annual growth rate of 16.4%. Net profit grew from Rs 10,291 crore in FY22 to Rs 19,159 crore in FY26, which works out to a compound annual growth rate of 16.8%. In the June 2026 quarter, revenue grew 8.1% year on year to Rs 70,318 crore, while net profit rose 15.2% to Rs 4,983 crore. The company has a return on equity of 14.7%, a debt to equity ratio of 1.15 and a market capitalisation of Rs 501,514 crore. The stock trades at a P/E of 25.6, above the industry P/E of 21.9. Looking ahead, the company has a very large order book across infrastructure, energy and hydrocarbon projects, supported by government capital spending. Its growing technology and green energy businesses widen its sources of growth.

What risks should investors check before buying pharma, fertiliser and engineering major stocks?

Ans. Investors should check a few risks before buying pharma, fertiliser and engineering major stocks. Regulatory approvals. Plant inspections and approvals can affect supplies. Season and monsoon. Crop protection sales follow rain and pest cycles. Order timing. Project awards can shift between periods. Reading the latest results presentation and comparing each company with its peers helps judge how these risks apply to each stock.

Is this list of pharma, fertiliser and engineering major stocks investment advice?

Ans. No. This article is educational and uses publicly available data as of the 16 November 2026 close. Please verify figures on NSE and BSE, read company filings and consult a SEBI registered adviser before investing. Univest is SEBI registered research analyst INH000013776.

Recent Articles

Note: This blog is for information purpose only. Investments and trading are subject to market risks, read all scheme related documents carefully.

Reviews

user-review-1
user-review-2
user-review-3
user-review-4
user-review-5

RESEARCH ANALYST

Get SEBI Registered
advice on the stocks
trending today.

Get 3 FREE Trade Ideas

+91
for Startups Accelerator 2024

for Startups Accelerator 2024

Trusted by 1Cr Indians

Trusted by 1Cr Indians

Awarded No.1 by Economic Times

Awarded No.1 by Economic Times

GET THE APP

Join 1Cr users today.

SEBI Registered Analyst-backed Picks. Free Demat. One App

  • Free Demat account in under 5 minutes
  • Live market data — Nifty, Sensex, sector insights
  • SEBI Registered analyst-backed stock picks
Get it on Google PlayDownload on the App Store
Stocks:
All|a|b|c|d|e|f|g|h|i|j|k|l|m|n|o|p|q|r|s|t|u|v|w|x|y|z

Copyright 2026 Univest. All rights reserved.
Designed with ❤️ in India

arrow down